tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2022-100-8-54-64tiblj-1669Research ArticleОБЗОРREVIEWПрепараты для краткосрочной химиотерапии лекарственно-устойчивого туберкулеза и их влияние на организм человекаMedications for Short-Course Chemotherapy of Drug Resistant Tuberculosis and Their Effect on the HostМожокинаГ. Н.MozhokinaG. N.

Можокина Галина Николаевна, доктор медицинских наук, ведущий научный сотрудник научной лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции

127473, Москва, ул. Достоевского, д. 4, к. 2

Galina N. Mozhokina, Doctor of Medical Sciences, Leading Researcher of Research Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection

Build. 2, 4, Dostoevskiy St., Moscow, 127473

mojokina@mail.ruhttps://orcid.org/0000-0001-6596-9777СамойловаА. Г.SamoylovaA. G.

Самойлова Анастасия Геннадьевна, доктор медицинских наук, первый заместитель директора по научной работе

127473, Москва, ул. Достоевского, д. 4, к. 2

Anastasiya G. Samoylova, Doctor of Medical Sciences, First Deputy Deputy Director for Research

Build. 2, 4, Dostoevskiy St., Moscow, 127473

a.samoilova.nmrc@mail.ruhttps://orcid.org/0000-0002-0637-7955ВасильеваИ. А.VasilyevaI. A.

Васильева Ирина Анатольевна, доктор медицинских наук, профессор, директор

127473, Москва, ул. Достоевского, д. 4, к. 2Тел.: + 7 (495) 6311515, доб. 1001

Irina A. Vasilyeva, Doctor of Medical Sciences, Professor, Director

Build. 2, 4, Dostoevskiy St., Moscow, 127473Phone: + 7 (495) 6311515, ext. 1001

nmrc@nmrc.ruРусскихА. Е.RusskikhA. E.

Русских Анастасия Евгеньевна, научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, Москва, ул. Достоевского, д. 4, к. 2

Anastasia E. Russkikh, Researcher of Department of Differential Diagnostics and Treatment of Tuberculosis and Concurrent Infections

Build. 2, 4, Dostoevskiy St., Moscow, 127473

ana-lobach@yandex.ruФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian Federation20221009202210085464Copyright © Можокина Г.Н., Самойлова А.Г., Васильева И.А., Русских А.Е., 20222022Можокина Г.Н., Самойлова А.Г., Васильева И.А., Русских А.Е.Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Russkikh A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1669

В обзоре представлены актуальные данные из 88 источников литературы, касающиеся краткосрочных схем лечения туберкулеза с множественной лекарственной устойчивостью возбудителя с характеристикой наиболее эффективных препаратов ‒ бедаквилина, линезолида, деламанида, клофазимина. Также приведены сведения о дополнительных свойствах препаратов ‒ модулировать ключевые иммунные реакции и иммунометаболические процессы, которые лежат в основе нового подхода к совершенствованию лечения туберкулеза – терапии хозяина.

The review presents up-to-date data from 88 publications devoted to the short-course regimens of multiple drug resistant tuberculosis treatment and describes characteristics of the most effective drugs – bedaquiline, linezolid, delamanid, and clofazimine. Information is also provided on the additional properties of the drugs, i.e. modulation of the key immune response and immunometabolic processes that underlie a new approach to improvement of tuberculosis treatment, the so-called host therapy.

лекарственно-устойчивый туберкулезмножественная лекарственная устойчивостькраткосрочные схемы леченияпротивотуберкулезные препаратытерапия хозяинаdrug resistant tuberculosismultiple drug resistanceshort-course treatment regimensanti-tuberculosis drugshost therapyReferencesВасильева И. А., Самойлова А. Г., Рудакова А. В., Ловачева О. В., Глебов К. А., Черноусова Л. Н. Экономическое обоснование применения новых схем химиотерапии для лечения больных туберкулезом с широкой лекарственной устойчивостью // Туб. и болезни легких. – 2018. – Т. 96, № 6. – С. 7-14. DOI: 10.21292/2075-1230-2018-96-6-7-14.Vasilyeva I.A., Samoylova A.G., Rudakova A.V., Lovacheva O.V., Glebov K.A., Chernousova L.N. Economic feasibility of new chemotherapy regimens for treatment of tuberculosis patients with extensive drug resistance. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 7-14. (In Russ.) doi: 10.21292/2075-1230-2018-96-6-7-14.Иванова Д. А., Борисов С. Е., Родина О. В., Филиппов А. В., Иванушкина Т. Н., Литвинова Н. В. Безопасность режимов лечения больных туберкулезом с множественной лекарственной устойчивостью возбудителя согласно новым рекомендациям ВОЗ 2019 г. // Туб. и болезни легких. ‒ 2020. ‒ Т. 98, № 1. ‒ С. 5-15.Ivanova D.A., Borisov S.E., Rodina O.V., Filippov A.V., Ivanushkina T.N., Litvinova N.V. Safety of treatment regimens in multiple drug resistant tuberculosis patients compiled as per the new WHO recommendations as of 2019. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 1, pp. 5-15. (In Russ.)Кубанов А. А., Карамова А. Э., Воронцова А. А., Калинина П. А. Фармакотерапия лепры // Вестник дерматологии и венерологии. ‒ 2016. ‒ № 4. ‒ С. 12-19.Kubanov A.A., Karamova A.E., Vorontsova A.A., Kalinina P.A. Drug therapy of leprosy. Vestnik Dermatologii i Venerologii, 2016, no. 4, pp. 12-19. (In Russ.)Можокина Г. Н., Самойлова А. Г. Клофазимин: история и перспективы // Туб. и болезни легких. – 2021. – Т. 99, № 5. – С. 64-70. http://doi.org/10.21292/2075-1230-2021-99-5-64-70.Mozhokina G.N., Samoylova A.G. Clofazimine: history and perspectives. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 5, pp. 64-70. (In Russ.) http://doi.org/10.21292/2075-1230-2021-99-5-64-70.Можокина Г. Н., Самойлова А. Г., Васильева И. А. Проблема нейротоксичности лекарственных препаратов при лечении больных туберкулезом // Туб. и болезни легких. – 2020. – Т. 98, № 10. – С. 58-63. http://doi.org/10.21292/2075-1230-2020-98-10-58-63.G. N. Mozhokina, A. G. Samoylova, and I. A. Vasilyeva. The problem of neurotoxicity of drugs in the treatment of tuberculosis patients. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 10, pp. 58-63. (In Russ.) http://doi.org/10.21292/2075-1230-2020-98-10-58-63.Русских А. Е., Кутузова Д. М., Ловачева О. В., Самойлова А. Г., Васильева И. А. Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы// Туб. и болезни легких. – 2020. – Т. 98, № 12. С. 57-66. http://doi.org/10.21292/2075-1230-2020-98-12-57-66.Russkikh A.E., Kutuzova D.M., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A. Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 12, pp. 57-66. (In Russ.) http://doi.org/10.21292/2075-1230-2020-98-12-57-66.Туберкулез у взрослых. Клинические рекомендации. 2020. [Electronic resource]. URL: https://cr.minzdrav.gov.ru/recomend/16_1 (accessed: 27.09.2021)].Tuberkulez u vzroslykh. Klinicheskie rekomendatsii. [Tuberculosis in adults. Guidelines]. 2020, Epub., Available: https://cr.minzdrav.gov.ru/recomend/16_1 (Accessed: 27.09.2021).Adikesavalu H., Gopalaswamy R., Kumar A., Ranganathan U. D., Shanmugam S. Autophagy induction as a host-directed therapeutic strategy against Mycobacterium tuberculosis infection // Medicina (Kaunas). ‒ 2021. ‒ Vol. 57, № 6. ‒ Р. 522.Adikesavalu H., Gopalaswamy R., Kumar A., Ranganathan U. D., Shanmugam S. Autophagy induction as a host-directed therapeutic strategy against Mycobacterium tuberculosis infection // Medicina (Kaunas). ‒ 2021. ‒ Vol. 57, № 6. ‒ Р. 522.Agyeman A. A., Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis // Ann. Clin. Microbiol. Antimicrob. – 2016. ‒ Vol. 15, № 1. – Р. 1-17.Agyeman A. A., Ofori-Asenso R. Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis // Ann. Clin. Microbiol. Antimicrob. – 2016. ‒ Vol. 15, № 1. – Р. 1-17.Ahmad S., Bhattacharya D., Gupta N., Rawat V., Tousif S., Van Kaer L., Das G. Clofazimine enhances the efficacy of BCG revaccination via stem cell-like memory T cells // PLoS Pathog. ‒ 2020. ‒ Vol. 16, № 5. ‒ Р. e1008356.Ahmad S., Bhattacharya D., Gupta N., Rawat V., Tousif S., Van Kaer L., Das G. Clofazimine enhances the efficacy of BCG revaccination via stem cell-like memory T cells // PLoS Pathog. ‒ 2020. ‒ Vol. 16, № 5. ‒ Р. e1008356.Andries K., Verhasselt P., Guillemont J., Göhlmann H. W., Neefs J. M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., Williams P., de Chaffoy D., Huitric E., Hoffner S., Cambau E., Truffot-Pernot C., Lounis N., Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis // Science. ‒ 2005. ‒ Vol. 307 (5707). ‒ Р. 223-227.Andries K., Verhasselt P., Guillemont J., Göhlmann H. W., Neefs J. M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., Williams P., de Chaffoy D., Huitric E., Hoffner S., Cambau E., Truffot-Pernot C., Lounis N., Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis // Science. ‒ 2005. ‒ Vol. 307 (5707). ‒ Р. 223-227.Apodaca A. A., Rakita R. M. Linezolid-induced lactic acidosis // N. Engl. J. Med. ‒ 2003. ‒ Vol. 348. ‒ Р. 86-87.Apodaca A. A., Rakita R. M. Linezolid-induced lactic acidosis // N. Engl. J. Med. ‒ 2003. ‒ Vol. 348. ‒ Р. 86-87.Avaliani T., Sereda Y., Davtyan H., Tukvadze N., Togonidze T., Kiria N., Denisiuk O., Gozalov O., Ahmedov S, Hovhannesyan A. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020 // Monaldi Arch. Chest Dis. ‒ 2021. ‒ Vol. 91, № 1.Avaliani T., Sereda Y., Davtyan H., Tukvadze N., Togonidze T., Kiria N., Denisiuk O., Gozalov O., Ahmedov S, Hovhannesyan A. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020 // Monaldi Arch. Chest Dis. ‒ 2021. ‒ Vol. 91, № 1.Belosludtsev K. N., Belosludtseva N. V., Talanov E. Y., Tenkov K. S., Starinets V. S., Agafonov A. V., Pavlik L. L., Dubinin M. V. Effect of bedaquiline on the functions of rat liver mitochondria // Biochim. Biophys. Acta Biomembr. 2019. ‒ Vol. 1861, № 1. ‒ Р. 288-297.Belosludtsev K. N., Belosludtseva N. V., Talanov E. Y., Tenkov K. S., Starinets V. S., Agafonov A. V., Pavlik L. L., Dubinin M. V. Effect of bedaquiline on the functions of rat liver mitochondria // Biochim. Biophys. Acta Biomembr. 2019. ‒ Vol. 1861, № 1. ‒ Р. 288-297.Bernstein W. B., Trotta R. F., Rector J. T., Tjaden J. A., Barile A. J. Mechanisms for linezolid-induced anemia and thrombocytopenia // Ann. Pharmacother. 2003. ‒ Vol. 37, № 4. ‒ Р. 517-520.Bernstein W. B., Trotta R. F., Rector J. T., Tjaden J. A., Barile A. J. Mechanisms for linezolid-induced anemia and thrombocytopenia // Ann. Pharmacother. 2003. ‒ Vol. 37, № 4. ‒ Р. 517-520.Bezerra E. L., Vilar M. J., da Trindade Neto P. B., Sato E. I. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus // Arthritis Rheum. ‒ 2005. Vol. 52, № 10. ‒ Р. 3073-3078.Bezerra E. L., Vilar M. J., da Trindade Neto P. B., Sato E. I. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus // Arthritis Rheum. ‒ 2005. Vol. 52, № 10. ‒ Р. 3073-3078.Blair H. A., Scott L. J. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis // Drugs. ‒ 2015. ‒ Vol. 75, № 1. ‒ Р. 91‐100.Blair H. A., Scott L. J. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis // Drugs. ‒ 2015. ‒ Vol. 75, № 1. ‒ Р. 91‐100.Borisov S. E., Dheda K., Enwerem M., Romero Leyet R., Migliori G. B. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study // Eur. Respir J. ‒ 2017. ‒ Vol. 49, № 5. ‒ Р. 1700387.Borisov S. E., Dheda K., Enwerem M., Romero Leyet R., Migliori G. B. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study // Eur. Respir J. ‒ 2017. ‒ Vol. 49, № 5. ‒ Р. 1700387.Bressler A. M., Zimmer S. M., Gilmore J. L., Somani J. Peripheral neuropathy associated with prolonged use of linezolid // Lancet Infect. Dis. ‒ 2004. ‒ Vol. 4, № 8. ‒ Р. 528-531.Bressler A. M., Zimmer S. M., Gilmore J. L., Somani J. Peripheral neuropathy associated with prolonged use of linezolid // Lancet Infect. Dis. ‒ 2004. ‒ Vol. 4, № 8. ‒ Р. 528-531.Cahill C., Phelan J. J., Keane J. Understanding and exploiting the effect of tuberculosis antimicrobials on host mitochondrial function and bioenergetics // Front. Cell. Infect. Microbiol. ‒ 2020. ‒ Vol. 10. ‒ Р. 493.Cahill C., Phelan J. J., Keane J. Understanding and exploiting the effect of tuberculosis antimicrobials on host mitochondrial function and bioenergetics // Front. Cell. Infect. Microbiol. ‒ 2020. ‒ Vol. 10. ‒ Р. 493.Chandra P., He L., Zimmerman M., Yang G., Köster S., Ouimet M., Wang H., Moore K. J., Dartois V., Schilling J. D., Philips J. A. Inhibition of fatty acid oxidation promotes macrophage control of Mycobacterium tuberculosis // mBio. 2020. ‒ Vol. 11, № 4. ‒ Р. e01139-20.Chandra P., He L., Zimmerman M., Yang G., Köster S., Ouimet M., Wang H., Moore K. J., Dartois V., Schilling J. D., Philips J. A. Inhibition of fatty acid oxidation promotes macrophage control of Mycobacterium tuberculosis // mBio. 2020. ‒ Vol. 11, № 4. ‒ Р. e01139-20.Chen M., Gan, H., Remold, H. G. A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv, but not attenuated H37Ra, causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis // J. Immunol. ‒ 2006. ‒ Vol. 176. ‒ Р. 3707-3716.Chen M., Gan, H., Remold, H. G. A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv, but not attenuated H37Ra, causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis // J. Immunol. ‒ 2006. ‒ Vol. 176. ‒ Р. 3707-3716.Chiang C. Y., Lin C. J. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries // Indian J. Tuberc. ‒ 2020. ‒ Vol. 67 (4S). ‒ Р. S16-S22.Chiang C. Y., Lin C. J. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries // Indian J. Tuberc. ‒ 2020. ‒ Vol. 67 (4S). ‒ Р. S16-S22.Collaborative group for the meta-analysis of individual patient data in MDR-TB treatment–2017, Ahmad N., Ahuja S. D., Menzies D. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis // Lancet. ‒ 2018. ‒ Vol. 392 (10150). ‒ Р. 821-834.Collaborative group for the meta-analysis of individual patient data in MDR-TB treatment–2017, Ahmad N., Ahuja S. D., Menzies D. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis // Lancet. ‒ 2018. ‒ Vol. 392 (10150). ‒ Р. 821-834.Cox D. J., Coleman A. M., Gogan K. M., Phelan J. J., Ó Maoldomhnaigh C., Dunne P. J., Basdeo S. A., Keane J. Inhibiting histone deacetylases in human macrophages promotes glycolysis, IL-1β, and T helper cell responses to Mycobacterium tuberculosis // Front Immunol. ‒ 2020. ‒ Vol. 11. ‒ Р. 1609.Cox D. J., Coleman A. M., Gogan K. M., Phelan J. J., Ó Maoldomhnaigh C., Dunne P. J., Basdeo S. A., Keane J. Inhibiting histone deacetylases in human macrophages promotes glycolysis, IL-1β, and T helper cell responses to Mycobacterium tuberculosis // Front Immunol. ‒ 2020. ‒ Vol. 11. ‒ Р. 1609.Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis // Int. J. Tuberc. Lung Dis. – 2012. ‒ Vol. 16, № 4. – Р. 447-454.Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis // Int. J. Tuberc. Lung Dis. – 2012. ‒ Vol. 16, № 4. – Р. 447-454.Cox V., Furin J. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied? // Int. J. Tuberc. Lung Dis. ‒ 2017. ‒ Vol. 21, № 12. ‒ Р. 1211-1213.Cox V., Furin J. World Health Organization recommendations for multidrug-resistant tuberculosis: should different standards be applied? // Int. J. Tuberc. Lung Dis. ‒ 2017. ‒ Vol. 21, № 12. ‒ Р. 1211-1213.Cumming B. M., Addicott K. W., Adamson J. H., Steyn A. J. Mycobacterium tuberculosis induces decelerated bioenergetic metabolism in human macrophages // Elife. ‒ 2018. ‒ Vol. 7. ‒ Р. e39169.Cumming B. M., Addicott K. W., Adamson J. H., Steyn A. J. Mycobacterium tuberculosis induces decelerated bioenergetic metabolism in human macrophages // Elife. ‒ 2018. ‒ Vol. 7. ‒ Р. e39169.De Vriese A. S., Van Coster R., Smet J., Seneca S., Lovering A., Van Haute L., Boelaert J. R. Linezolid-induced inhibition of mitochondrial protein synthesis // Clin. Infect. Dis. ‒ 2006. ‒ Vol. 42. ‒ Р. 1111-1117.De Vriese A. S., Van Coster R., Smet J., Seneca S., Lovering A., Van Haute L., Boelaert J. R. Linezolid-induced inhibition of mitochondrial protein synthesis // Clin. Infect. Dis. ‒ 2006. ‒ Vol. 42. ‒ Р. 1111-1117.Dheda K., Cox H., Esmail A., Wasserman S.., Chang K. C., Lange C. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? // Respirology. ‒ 2018. ‒ Vol. 23, № 1. ‒ Р. 36-45.Dheda K., Cox H., Esmail A., Wasserman S.., Chang K. C., Lange C. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? // Respirology. ‒ 2018. ‒ Vol. 23, № 1. ‒ Р. 36-45.Diacon A. H., Dawson R., Hanekom M., Narunsky K., Venter A., Hittel N., Geiter L. J., Wells C. D., Paccaly A. J., Donald P. R. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients // Int. J. Tuberc. Lung Dis. – 2011. ‒ Vol. 15, № 7. – Р. 949-954.Diacon A. H., Dawson R., Hanekom M., Narunsky K., Venter A., Hittel N., Geiter L. J., Wells C. D., Paccaly A. J., Donald P. R. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients // Int. J. Tuberc. Lung Dis. – 2011. ‒ Vol. 15, № 7. – Р. 949-954.Diacon A. H., Pym A., Grobusch M. P., de los Rios J. M., Gotuzzo E., Vasilyeva I., Leimane V., Andries K., Bakare N., De Marez T., Haxaire-Theeuwes M., Lounis N., Meyvisch P., De Paepe E., van Heeswijk R. P., Dannemann B. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline // N. Engl. J. Med. ‒ 2014. ‒ Vol. 371, № 8. ‒ Р. 723-732.Diacon A. H., Pym A., Grobusch M. P., de los Rios J. M., Gotuzzo E., Vasilyeva I., Leimane V., Andries K., Bakare N., De Marez T., Haxaire-Theeuwes M., Lounis N., Meyvisch P., De Paepe E., van Heeswijk R. P., Dannemann B. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline // N. Engl. J. Med. ‒ 2014. ‒ Vol. 371, № 8. ‒ Р. 723-732.Doan T. N., Cao P., Emeto T. I., McCaw J. M., McBryde E. S. Predicting the outcomes of new short-course regimens for multidrug-resistant tuberculosis using intrahost and pharmacokinetic-pharmacodynamic modeling // Antimicrob. Agents. Chemother. ‒ 2018. ‒ Vol. 62, № 12. ‒ Р. e01487-18.Doan T. N., Cao P., Emeto T. I., McCaw J. M., McBryde E. S. Predicting the outcomes of new short-course regimens for multidrug-resistant tuberculosis using intrahost and pharmacokinetic-pharmacodynamic modeling // Antimicrob. Agents. Chemother. ‒ 2018. ‒ Vol. 62, № 12. ‒ Р. e01487-18.Duan H., Chen X., Li Z., Pang Y., Jing W., Liu P., Wu T., Cai C., Chu N., Xu S. et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial // Clin. Microbiol. Infect. ‒ Vol. 25, № 2. ‒ Р. 190-195.Duan H., Chen X., Li Z., Pang Y., Jing W., Liu P., Wu T., Cai C., Chu N., Xu S. et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial // Clin. Microbiol. Infect. ‒ Vol. 25, № 2. ‒ Р. 190-195.Dubey R. K. Assuming the role of mitochondria in mycobacterial infection // Int. J. Mycobacteriol. ‒ 2016. ‒ Vol. 5. ‒ Р. 379-383.Dubey R. K. Assuming the role of mitochondria in mycobacterial infection // Int. J. Mycobacteriol. ‒ 2016. ‒ Vol. 5. ‒ Р. 379-383.Duewelhenke N., Krut O., Eysel P. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines // Antimicrob. Agents Chemother. ‒ 2007. ‒ Vol. 51, № 1. ‒ Р. 54-63.Duewelhenke N., Krut O., Eysel P. Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines // Antimicrob. Agents Chemother. ‒ 2007. ‒ Vol. 51, № 1. ‒ Р. 54-63.du Preez I., Loots D. T. New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa // Tuberculosis (Edinb). ‒ 2013. ‒ Vol. 93, № 3. ‒ Р. 330-337.du Preez I., Loots D. T. New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa // Tuberculosis (Edinb). ‒ 2013. ‒ Vol. 93, № 3. ‒ Р. 330-337.Fine-Coulson K., Giguère S., Quinn F. D., Reaves B. J. Infection of A5A49 human type II epithelial cells with Mycobacterium tuberculosis induces changes in mitochondrial morphology, distribution and mass that are dependent on the early secreted antigen, ESAT-6 // Microb. Infect. ‒ 2015. ‒ Vol. 17. ‒ Р. 689-697.Fine-Coulson K., Giguère S., Quinn F. D., Reaves B. J. Infection of A5A49 human type II epithelial cells with Mycobacterium tuberculosis induces changes in mitochondrial morphology, distribution and mass that are dependent on the early secreted antigen, ESAT-6 // Microb. Infect. ‒ 2015. ‒ Vol. 17. ‒ Р. 689-697.Fiorillo M., Lamb R., Tanowitz H. B., Cappello A. R., Martinez-Outschoorn U. E., Sotgia F., Lisanti M. P. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs) // Aging (Albany NY). ‒ 2016. ‒ Vol. 8, № 8. ‒ Р. 1593-1607.Fiorillo M., Lamb R., Tanowitz H. B., Cappello A. R., Martinez-Outschoorn U. E., Sotgia F., Lisanti M. P. Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs) // Aging (Albany NY). ‒ 2016. ‒ Vol. 8, № 8. ‒ Р. 1593-1607.Frippiat F., Bergiers C., Michel C., Dujardin J. P., Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy // J. Antimicrob. Chemother. ‒ 2004. ‒ Vol. 53, № 6. ‒ 1114-1115.Frippiat F., Bergiers C., Michel C., Dujardin J. P., Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy // J. Antimicrob. Chemother. ‒ 2004. ‒ Vol. 53, № 6. ‒ 1114-1115.Fujiwara M., Kawasaki M., Hariguchi N., Liu Y., Matsumoto M. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis // Tuberculosis (Edinb). ‒ 2018. ‒ Vol. 108. ‒ Р. 186-194.Fujiwara M., Kawasaki M., Hariguchi N., Liu Y., Matsumoto M. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis // Tuberculosis (Edinb). ‒ 2018. ‒ Vol. 108. ‒ Р. 186-194.Fukutomi Y., Maeda Y., Makino M. Apoptosis-inducing activity of clofazimine in macrophages // Antimicrob. Agents. Chemother. ‒ 2011. ‒ Vol. 55, № 9. ‒ Р. 4000-4005.Fukutomi Y., Maeda Y., Makino M. Apoptosis-inducing activity of clofazimine in macrophages // Antimicrob. Agents. Chemother. ‒ 2011. ‒ Vol. 55, № 9. ‒ Р. 4000-4005.Garrabou G., Soriano À., Pinós T., Casanova-Mollà J., Pacheu-Grau D., Morén C., Cardellach F. et al. Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers // Antimicrob. Agents Chemother. ‒ 2017. ‒ Vol. 61, № 9. ‒ Р. e00542-17.Garrabou G., Soriano À., Pinós T., Casanova-Mollà J., Pacheu-Grau D., Morén C., Cardellach F. et al. Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers // Antimicrob. Agents Chemother. ‒ 2017. ‒ Vol. 61, № 9. ‒ Р. e00542-17.Genestet C., Bernard-Barret F., Hodille E., Ginevra C., Ader F., Goutelle S., Lina G., Dumitrescu O. Lyon TB study group. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages //Tuberculosis (Edinb). ‒ 2018. ‒ Vol. 111. ‒ Р. 67-70.Genestet C., Bernard-Barret F., Hodille E., Ginevra C., Ader F., Goutelle S., Lina G., Dumitrescu O. Lyon TB study group. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages //Tuberculosis (Edinb). ‒ 2018. ‒ Vol. 111. ‒ Р. 67-70.Giraud-Gatineau A., Coya J. M., Maure A., Biton A., Thomson M., Bernard E. M., Marrec J., Gutierrez M. G., Larrouy-Maumus G., Brosch R., Gicquel B., Tailleux L. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection // Elife. ‒ 2020. ‒ Vol. 9. ‒ Р. e55692.Giraud-Gatineau A., Coya J. M., Maure A., Biton A., Thomson M., Bernard E. M., Marrec J., Gutierrez M. G., Larrouy-Maumus G., Brosch R., Gicquel B., Tailleux L. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection // Elife. ‒ 2020. ‒ Vol. 9. ‒ Р. e55692.Gleeson L. E., Sheedy F. J., Palsson-McDermott E. M., Triglia D., O'Leary S. M., O'Sullivan M. P., O'Neill L. A., Keane J. Cutting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication // J. Immunol. ‒ 2016. ‒ Vol. 196, № 6. ‒ Р. 2444-2449.Gleeson L. E., Sheedy F. J., Palsson-McDermott E. M., Triglia D., O'Leary S. M., O'Sullivan M. P., O'Neill L. A., Keane J. Cutting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication // J. Immunol. ‒ 2016. ‒ Vol. 196, № 6. ‒ Р. 2444-2449.Gler M. T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J. L., Vargas-Vasquez D. E., Wells C. D. et al. Delamanid for multidrug-resistant pulmonary tuberculosis // N. Engl. J. Med. ‒ 2012. ‒ Vol. 366, № 23. Р. 2151-2160. doi: 10.1056/NEJMoa1112433.Gler M. T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J. L., Vargas-Vasquez D. E., Wells C. D. et al. Delamanid for multidrug-resistant pulmonary tuberculosis // N. Engl. J. Med. ‒ 2012. ‒ Vol. 366, № 23. Р. 2151-2160. doi: 10.1056/NEJMoa1112433.Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.Han W. M., Mahikul W., Pouplin T., Lawpoolsri S., White L. J., Pan-Ngum W. Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach // PLoS One. ‒ 2021. ‒ Vol. 16, № 3. ‒ Р. e0248846.Han W. M., Mahikul W., Pouplin T., Lawpoolsri S., White L. J., Pan-Ngum W. Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach // PLoS One. ‒ 2021. ‒ Vol. 16, № 3. ‒ Р. e0248846.Highlights of prescribing information [Electronic resource]. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019500s013lbl.pdf (accessed: 02.09.2021).Highlights of prescribing information [Electronic resource]. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019500s013lbl.pdf (accessed: 02.09.2021).Horter S., Stringer B., Gray N., Parpieva N., Safaev K., Tigay Z., Singh J., Achar J. Person-centred care in practice: Perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan // BMC Infect. Dis. ‒ 2020. ‒ Vol. 20. ‒ Р. 675.Horter S., Stringer B., Gray N., Parpieva N., Safaev K., Tigay Z., Singh J., Achar J. Person-centred care in practice: Perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan // BMC Infect. Dis. ‒ 2020. ‒ Vol. 20. ‒ Р. 675.Huang L., Nazarova E. V., Russell D. G. Mycobacterium tuberculosis: bacterial fitness within the host macrophage // Microbiol. Spectr. ‒ 2019. ‒ Vol. 7, № 2. Р. 10. 1128.Huang L., Nazarova E. V., Russell D. G. Mycobacterium tuberculosis: bacterial fitness within the host macrophage // Microbiol. Spectr. ‒ 2019. ‒ Vol. 7, № 2. Р. 10. 1128.Ibrahim M., Andries K., Lounis N., Chauffour A., Truffot-Pernot C., Jarlier V., Veziris N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis // Antimicrob. Agents Chemother. ‒ 2007. ‒ Vol. 51. Р. 1011-1015.Ibrahim M., Andries K., Lounis N., Chauffour A., Truffot-Pernot C., Jarlier V., Veziris N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis // Antimicrob. Agents Chemother. ‒ 2007. ‒ Vol. 51. Р. 1011-1015.Kalghatgi S., Spina C. S., Costello J. C., Liesa M., Morones-Ramirez J. R., Slomovic S., Molina A., Shirihai O. S., Collins J. J. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells // Sci. Transl. Med. ‒ 2013. ‒ Vol. 5, № 192. ‒ Р. 192ra85.Kalghatgi S., Spina C. S., Costello J. C., Liesa M., Morones-Ramirez J. R., Slomovic S., Molina A., Shirihai O. S., Collins J. J. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in Mammalian cells // Sci. Transl. Med. ‒ 2013. ‒ Vol. 5, № 192. ‒ Р. 192ra85.Kaufmann S. H. E., Dorhoi A., Hotchkiss R. S., Bartenschlager R. Host-directed therapies for bacterial and viral infections // Nat. Rev. Drug. Discov. ‒ 2018. Vol. 17, № 1. ‒ Р. 35-56.Kaufmann S. H. E., Dorhoi A., Hotchkiss R. S., Bartenschlager R. Host-directed therapies for bacterial and viral infections // Nat. Rev. Drug. Discov. ‒ 2018. Vol. 17, № 1. ‒ Р. 35-56.Khoshnood S., Taki E., Sadeghifard N., Kaviar V. H., Haddadi M. H., Farshadzadeh Z., Kouhsari E., Goudarzi M., Heidary M. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis // Front. Microbiol. ‒ 2021. Vol. 12. ‒ Р. 717045.Khoshnood S., Taki E., Sadeghifard N., Kaviar V. H., Haddadi M. H., Farshadzadeh Z., Kouhsari E., Goudarzi M., Heidary M. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis // Front. Microbiol. ‒ 2021. Vol. 12. ‒ Р. 717045.Kilinc G., Saris A., Ottenhoff T. H. M., Haks M. C. Host-directed therapy to combat mycobacterial infections // Immunol. Rev. ‒ 2021. ‒ Vol. 301, № 1. Р. 62-83.Kilinc G., Saris A., Ottenhoff T. H. M., Haks M. C. Host-directed therapy to combat mycobacterial infections // Immunol. Rev. ‒ 2021. ‒ Vol. 301, № 1. Р. 62-83.Kim Y.-R., Yang C.-S. Host-Directed therapeutics as a novel approach for tuberculosis treatment // J. Microbiol. Biotechnol. ‒ 2017. ‒ Vol. 27, № 9. Р. 1549-1558.Kim Y.-R., Yang C.-S. Host-Directed therapeutics as a novel approach for tuberculosis treatment // J. Microbiol. Biotechnol. ‒ 2017. ‒ Vol. 27, № 9. Р. 1549-1558.Kiran D., Podell B. K., Chambers M., Basaraba R. J. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review // Semin. Immunopathol. ‒ 2016. ‒ Vol. 38, № 2. ‒ Р. 167-183.Kiran D., Podell B. K., Chambers M., Basaraba R. J. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review // Semin. Immunopathol. ‒ 2016. ‒ Vol. 38, № 2. ‒ Р. 167-183.Koul A., Dendouga N., Vergauwen K., Molenberghs B., Vranckx L., Willebrords R., Ristic Z., Lill H., Dorange I., Guillemont J., Bald D., Andries K. Diarylquinolines target subunit c of mycobacterial ATP synthase // Nat. Chem. Biol. ‒ 2007. ‒ Vol. 3, № 6. ‒ Р. 323-324.Koul A., Dendouga N., Vergauwen K., Molenberghs B., Vranckx L., Willebrords R., Ristic Z., Lill H., Dorange I., Guillemont J., Bald D., Andries K. Diarylquinolines target subunit c of mycobacterial ATP synthase // Nat. Chem. Biol. ‒ 2007. ‒ Vol. 3, № 6. ‒ Р. 323-324.Lamprecht D. A., Finin P. M., Rahman M. A., Cumming B. M., Russell S. L., Jonnala S. R., Adamson J. H., Steyn A. J. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself // Nat. Commun. ‒ 2016. ‒ Vol. 7. Р. 12393.Lamprecht D. A., Finin P. M., Rahman M. A., Cumming B. M., Russell S. L., Jonnala S. R., Adamson J. H., Steyn A. J. Turning the respiratory flexibility of Mycobacterium tuberculosis against itself // Nat. Commun. ‒ 2016. ‒ Vol. 7. Р. 12393.Lifan Z., Sainan B., Feng S., Siyan Z., Xiaoqing L. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis // Int. J. Tuberc. Lung Dis. ‒ 2019. ‒ Vol. 23, № 12. ‒ Р. 1293-1307.Lifan Z., Sainan B., Feng S., Siyan Z., Xiaoqing L. Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis // Int. J. Tuberc. Lung Dis. ‒ 2019. ‒ Vol. 23, № 12. ‒ Р. 1293-1307.Liu Y., Matsumoto M., Ishida H., Ohguro K., Yoshitake M., Gupta R., Geiter L., Hafkin J. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB) // Tuberculosis (Edinb). ‒ 2018. Vol. 111. ‒ Р. 20-30.Liu Y., Matsumoto M., Ishida H., Ohguro K., Yoshitake M., Gupta R., Geiter L., Hafkin J. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB) // Tuberculosis (Edinb). ‒ 2018. Vol. 111. ‒ Р. 20-30.Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration // Antimicrob. Agents Chemother. ‒ 2006. ‒ Vol. 50, № 11. ‒ Р. 3543-3547.Lounis N., Veziris N., Chauffour A., Truffot-Pernot C., Andries K., Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration // Antimicrob. Agents Chemother. ‒ 2006. ‒ Vol. 50, № 11. ‒ Р. 3543-3547.Masuku S. D., Berhanu R., Van Rensburg C., Ndjeka N., Rosen S., Long L., Evans D., Nichols B. E. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis // Int. J. Tuberc. Lung Dis. ‒ 2020. ‒ Vol. 24, № 4. ‒ Р. 376-382.Masuku S. D., Berhanu R., Van Rensburg C., Ndjeka N., Rosen S., Long L., Evans D., Nichols B. E. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis // Int. J. Tuberc. Lung Dis. ‒ 2020. ‒ Vol. 24, № 4. ‒ Р. 376-382.Mirnejad R., Asadi A., Khoshnood S., Mirzaei H., Heidary M., Fattorini L., Ghodousi A., Darban-Sarokhalil D. Clofazimine: A useful antibiotic for drug-resistant tuberculosis // Biomed. Pharmacother. ‒ 2018. ‒ Vol. 105. Р. 1353-1359.Mirnejad R., Asadi A., Khoshnood S., Mirzaei H., Heidary M., Fattorini L., Ghodousi A., Darban-Sarokhalil D. Clofazimine: A useful antibiotic for drug-resistant tuberculosis // Biomed. Pharmacother. ‒ 2018. ‒ Vol. 105. Р. 1353-1359.Mpobela Agnarson A., Williams A., Kambili C., Mattson G., Metz L. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa // Expert. Rev. Anti-Infect. Ther. ‒ 2020. ‒ Vol. 18, № 5. ‒ Р. 475-483.Mpobela Agnarson A., Williams A., Kambili C., Mattson G., Metz L. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa // Expert. Rev. Anti-Infect. Ther. ‒ 2020. ‒ Vol. 18, № 5. ‒ Р. 475-483.Narita M., Tsuji B. T., Yu V. L. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome // Pharmacotherapy. 2007. ‒ Vol. 27, № 8. ‒ Р. 1189-1197.Narita M., Tsuji B. T., Yu V. L. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome // Pharmacotherapy. 2007. ‒ Vol. 27, № 8. ‒ Р. 1189-1197.Nunn A. J., Phillips P. P. J., Meredith S. K., Chiang C. Y., Conradie F., Dalai D., van Deun A., Rusen I. D. STREAM Study Collaborators. A trial of a shorter regimen for rifampin-resistant tuberculosis // N. Engl. J. Med. ‒ 2019. ‒ Vol. 380, № 13. ‒ Р. 1201-1213.Nunn A. J., Phillips P. P. J., Meredith S. K., Chiang C. Y., Conradie F., Dalai D., van Deun A., Rusen I. D. STREAM Study Collaborators. A trial of a shorter regimen for rifampin-resistant tuberculosis // N. Engl. J. Med. ‒ 2019. ‒ Vol. 380, № 13. ‒ Р. 1201-1213.Padayatchi N., Gopal M., Naidoo R., Werner L., Naidoo K., Master I., O'Donnell M. R. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study // J. Antimicrob. Chemother. ‒ 2014. ‒ Vol. 69, № 11. ‒ Р. 3103-3107.Padayatchi N., Gopal M., Naidoo R., Werner L., Naidoo K., Master I., O'Donnell M. R. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study // J. Antimicrob. Chemother. ‒ 2014. ‒ Vol. 69, № 11. ‒ Р. 3103-3107.Paik S., Kim J. K., Chung C., Jo E. K. Autophagy: A new strategy for host-directed therapy of tuberculosis // Virulence. ‒ 2019. ‒ Vol. 10, № 1. ‒ Р. 448-459.Paik S., Kim J. K., Chung C., Jo E. K. Autophagy: A new strategy for host-directed therapy of tuberculosis // Virulence. ‒ 2019. ‒ Vol. 10, № 1. ‒ Р. 448-459.Park H. E., Lee W., Shin M. K., Shin S. J. Understanding the reciprocal interplay between antibiotics and host immune system: how can we improve the anti-mycobacterial activity of current drugs to better control tuberculosis? // Front. Immunol. ‒ 2021. ‒ Vol. 12. ‒ Р. 703060.Park H. E., Lee W., Shin M. K., Shin S. J. Understanding the reciprocal interplay between antibiotics and host immune system: how can we improve the anti-mycobacterial activity of current drugs to better control tuberculosis? // Front. Immunol. ‒ 2021. ‒ Vol. 12. ‒ Р. 703060.Protti A., Ronchi D., Bassi G., Fortunato F., Bordoni A., Rizzuti T., Fumagalli R. Changes in whole-body oxygen consumption and skeletal muscle mitochondria during linezolid-induced lactic acidosis // Crit. Care Med. ‒ 2016. ‒ Vol. 44. Р. e5e79–e5e82.Protti A., Ronchi D., Bassi G., Fortunato F., Bordoni A., Rizzuti T., Fumagalli R. Changes in whole-body oxygen consumption and skeletal muscle mitochondria during linezolid-induced lactic acidosis // Crit. Care Med. ‒ 2016. ‒ Vol. 44. Р. e5e79–e5e82.Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). 2018.; WHO consolidated guidelines on tuberculosis. Module 4: treatment ‒ drug-resistant tuberculosis treatment. Geneva:World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). 2018.; WHO consolidated guidelines on tuberculosis. Module 4: treatment ‒ drug-resistant tuberculosis treatment. Geneva:World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.Santini A., Ronchi D., Garbellini M., Piga D., Protti A. Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes // Expert. Opin. Drug Saf. ‒ 2017. ‒ Vol. 16. ‒ Р. 833-843.Santini A., Ronchi D., Garbellini M., Piga D., Protti A. Linezolid-induced lactic acidosis: the thin line between bacterial and mitochondrial ribosomes // Expert. Opin. Drug Saf. ‒ 2017. ‒ Vol. 16. ‒ Р. 833-843.Soriano A., Miró O., Mensa J. Mitochondrial toxicity associated with linezolid // N. Engl. J. Med. ‒ 2005. ‒ Vol. 353. ‒ Р. 2305-2306.Soriano A., Miró O., Mensa J. Mitochondrial toxicity associated with linezolid // N. Engl. J. Med. ‒ 2005. ‒ Vol. 353. ‒ Р. 2305-2306.Tack I., Dumicho A., Ohler L., Shigayeva A., Bulti A. B., White K., Mbatha M., Furin J., Isaakidis P. Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high Human Immunodeficiency Virus (HIV) burden rural South Africa: A retrospective cohort analysis // Clin. Infect Dis. ‒ 2021. ‒ Vol. 73, № 9. ‒ Р. e3563-e3571.Tack I., Dumicho A., Ohler L., Shigayeva A., Bulti A. B., White K., Mbatha M., Furin J., Isaakidis P. Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high Human Immunodeficiency Virus (HIV) burden rural South Africa: A retrospective cohort analysis // Clin. Infect Dis. ‒ 2021. ‒ Vol. 73, № 9. ‒ Р. e3563-e3571.Tang S., Yao L., Hao X., Liu Y., Zeng L., Liu G., Li M., Li F., Wu M., Zhu Y., Sun H., Gu J., Wang X., Zhang Z. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China // Clin. Infect. Dis. ‒ 2015. ‒ Vol. 60, № 9. ‒ Р. 1361-1367.Tang S., Yao L., Hao X., Liu Y., Zeng L., Liu G., Li M., Li F., Wu M., Zhu Y., Sun H., Gu J., Wang X., Zhang Z. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China // Clin. Infect. Dis. ‒ 2015. ‒ Vol. 60, № 9. ‒ Р. 1361-1367.Trexel J., Yoon G. S., Keswani R. K., McHugh C., Yeomans L, Vitvitsky V., Banerjee R., Sud S., Sun Y., Rosania G. R., Stringer K. A. Macrophage-mediated clofazimine sequestration is accompanied by a shift in host energy metabolism // J. Pharm. Sci. ‒ 2017. ‒ Vol. 106, № 4. ‒ Р. 1162-1174.Trexel J., Yoon G. S., Keswani R. K., McHugh C., Yeomans L, Vitvitsky V., Banerjee R., Sud S., Sun Y., Rosania G. R., Stringer K. A. Macrophage-mediated clofazimine sequestration is accompanied by a shift in host energy metabolism // J. Pharm. Sci. ‒ 2017. ‒ Vol. 106, № 4. ‒ Р. 1162-1174.Ubeda C., Pamer E. G. Antibiotics, microbiota, and immune defense // Trends Immunol. ‒ 2012. ‒ Vol. 33. ‒ Р. 459-466.Ubeda C., Pamer E. G. Antibiotics, microbiota, and immune defense // Trends Immunol. ‒ 2012. ‒ Vol. 33. ‒ Р. 459-466.Veziris N., Ibrahim M., Lounis N., Andries K., Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis // PLoS One. ‒ 2011. ‒ Vol. 6, № 3. ‒ Р. e17556.Veziris N., Ibrahim M., Lounis N., Andries K., Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis // PLoS One. ‒ 2011. ‒ Vol. 6, № 3. ‒ Р. e17556.WHO consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment. Geneva:World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.WHO consolidated guidelines on tuberculosis. Module 4: treatment drug-resistant tuberculosis treatment. Geneva:World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.Winchell C. G., Mishra B. B., Phuah J. Y., Saqib M., Nelson S. J., Maiello P., Causgrove C. M., Ameel C. L., Stein B., Borish H. J., White A. G., Klein E. C., Zimmerman M. D., Dartois V., Lin P. L., Sassetti C. M., Flynn J. L. Evaluation of IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques // Front. Immunol. ‒ 2020. ‒ Vol. 11. ‒ Р. 891.Winchell C. G., Mishra B. B., Phuah J. Y., Saqib M., Nelson S. J., Maiello P., Causgrove C. M., Ameel C. L., Stein B., Borish H. J., White A. G., Klein E. C., Zimmerman M. D., Dartois V., Lin P. L., Sassetti C. M., Flynn J. L. Evaluation of IL-1 blockade as an adjunct to linezolid therapy for tuberculosis in mice and macaques // Front. Immunol. ‒ 2020. ‒ Vol. 11. ‒ Р. 891.Wu X., Li F., Wang X., Li C., Meng Q., Wang C., Huang J., Chen S., Zhu Z. Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism // Biochem. Biophys. Res. Commun. ‒ 2018. ‒ Vol. 495, № 1. ‒ Р. 267-272.Wu X., Li F., Wang X., Li C., Meng Q., Wang C., Huang J., Chen S., Zhu Z. Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism // Biochem. Biophys. Res. Commun. ‒ 2018. ‒ Vol. 495, № 1. ‒ Р. 267-272.Xu H. B., Jiang R. H., Xiao H. P. Clofazimine in the treatment of multidrug-resistant tuberculosis // Clin. Microbiol. Infect. ‒ 2012. ‒ Vol. 18, № 11. ‒ Р. 1104-1110.Xu H. B., Jiang R. H., Xiao H. P. Clofazimine in the treatment of multidrug-resistant tuberculosis // Clin. Microbiol. Infect. ‒ 2012. ‒ Vol. 18, № 11. ‒ Р. 1104-1110.Yang J. H., Bhargava P., McCloskey D., Mao N., Palsson B. O., Collins J. J. Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function // Cell. Host. Microbe. ‒ 2017. ‒ Vol. 22, № 6. ‒ Р. 757–765.e3.Yang J. H., Bhargava P., McCloskey D., Mao N., Palsson B. O., Collins J. J. Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function // Cell. Host. Microbe. ‒ 2017. ‒ Vol. 22, № 6. ‒ Р. 757–765.e3.Yoon G. S., Sud S., Keswani R. K., Baik J., Standiford T. J., Stringer K. A., Rosania G. R. Phagocytosed clofazimine biocrystals can modulate innate immune signaling by inhibiting TNFα and boosting IL-1RA secretion // Mol. Pharm. ‒ 2015. ‒ Vol. 12, № 7. ‒ Р. 2517-2527.Yoon G. S., Sud S., Keswani R. K., Baik J., Standiford T. J., Stringer K. A., Rosania G. R. Phagocytosed clofazimine biocrystals can modulate innate immune signaling by inhibiting TNFα and boosting IL-1RA secretion // Mol. Pharm. ‒ 2015. ‒ Vol. 12, № 7. ‒ Р. 2517-2527.Yoon G. S., Keswani R. K., Sud S., Rzeczycki P. M., Murashov M. D., Koehn T. A., Standiford T. J., Stringer K. A., Rosania G. R. Clofazimine biocrystal accumulation in macrophages upregulates interleukin 1 receptor antagonist production to induce a systemic anti-inflammatory state // Antimicrob. Agents Chemother. ‒ 2016. ‒ Vol. 60, № 6. ‒ Р. 3470-3479.Yoon G. S., Keswani R. K., Sud S., Rzeczycki P. M., Murashov M. D., Koehn T. A., Standiford T. J., Stringer K. A., Rosania G. R. Clofazimine biocrystal accumulation in macrophages upregulates interleukin 1 receptor antagonist production to induce a systemic anti-inflammatory state // Antimicrob. Agents Chemother. ‒ 2016. ‒ Vol. 60, № 6. ‒ Р. 3470-3479.

The authors declare that there are no conflicts of interest present.